Literature DB >> 21296887

Structure-guided antigen engineering yields pneumolysin mutants suitable for vaccination against pneumococcal disease.

Eliud O Oloo1, Jeremy A Yethon, Martina M Ochs, Bruce Carpick, Raymond Oomen.   

Abstract

Pneumolysin (PLY) is a cholesterol-binding, pore-forming protein toxin. It is an important virulence factor of Streptococcus pneumoniae and a key vaccine target against pneumococcal disease. We report a systematic structure-driven approach that solves a long-standing problem for vaccine development in this field: detoxification of PLY with retention of its antigenic integrity. Using three conformational restraint techniques, we rationally designed variants of PLY that lack hemolytic activity and yet induce neutralizing antibodies against the wild-type toxin. These results represent a key milestone toward a broad-spectrum protein-based pneumococcal vaccine and illustrate the value of structural knowledge in formulating effective strategies for antigen optimization.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21296887      PMCID: PMC3069417          DOI: 10.1074/jbc.M110.191148

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Influence of proline residues on protein conformation.

Authors:  M W MacArthur; J M Thornton
Journal:  J Mol Biol       Date:  1991-03-20       Impact factor: 5.469

2.  Comparison of pneumolysin genes and proteins from Streptococcus pneumoniae types 1 and 2.

Authors:  T J Mitchell; F Mendez; J C Paton; P W Andrew; G J Boulnois
Journal:  Nucleic Acids Res       Date:  1990-07-11       Impact factor: 16.971

3.  Pneumolysin, the thiol-activated toxin of Streptococcus pneumoniae, does not require a thiol group for in vitro activity.

Authors:  F K Saunders; T J Mitchell; J A Walker; P W Andrew; G J Boulnois
Journal:  Infect Immun       Date:  1989-08       Impact factor: 3.441

4.  Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae.

Authors:  R A Lock; J C Paton; D Hansman
Journal:  Microb Pathog       Date:  1988-12       Impact factor: 3.738

5.  Inhibition of human polymorphonuclear leukocyte respiratory burst, bactericidal activity, and migration by pneumolysin.

Authors:  J C Paton; A Ferrante
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

6.  Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae.

Authors:  J C Paton; R A Lock; D J Hansman
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

7.  The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197.

Authors:  G Giannini; R Rappuoli; G Ratti
Journal:  Nucleic Acids Res       Date:  1984-05-25       Impact factor: 16.971

8.  Stereochemical modeling of disulfide bridges. Criteria for introduction into proteins by site-directed mutagenesis.

Authors:  R Sowdhamini; N Srinivasan; B Shoichet; D V Santi; C Ramakrishnan; P Balaram
Journal:  Protein Eng       Date:  1989-11

9.  Inhibition of in vitro human lymphocyte response by the pneumococcal toxin pneumolysin.

Authors:  A Ferrante; B Rowan-Kelly; J C Paton
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

10.  Pneumolysin induces the salient histologic features of pneumococcal infection in the rat lung in vivo.

Authors:  C Feldman; N C Munro; P K Jeffery; T J Mitchell; P W Andrew; G J Boulnois; D Guerreiro; J A Rohde; H C Todd; P J Cole
Journal:  Am J Respir Cell Mol Biol       Date:  1991-11       Impact factor: 6.914

View more
  10 in total

1.  Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injury.

Authors:  Danielle Salha; Jason Szeto; Lisa Myers; Carol Claus; Anthony Sheung; Mei Tang; Belma Ljutic; David Hanwell; Karen Ogilvie; Marin Ming; Benjamin Messham; Germie van den Dobbelsteen; Robert Hopfer; Martina M Ochs; Scott Gallichan
Journal:  Infect Immun       Date:  2012-04-02       Impact factor: 3.441

Review 2.  Panel 6: Vaccines.

Authors:  Stephen I Pelton; Melinda M Pettigrew; Stephen J Barenkamp; Fabrice Godfroid; Carlos G Grijalva; Amanda Leach; Janak Patel; Timothy F Murphy; Sanja Selak; Lauren O Bakaletz
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

3.  Human antibodies to PhtD, PcpA, and Ply reduce adherence to human lung epithelial cells and murine nasopharyngeal colonization by Streptococcus pneumoniae.

Authors:  Ravinder Kaur; Naveen Surendran; Martina Ochs; Michael E Pichichero
Journal:  Infect Immun       Date:  2014-09-22       Impact factor: 3.441

4.  Crystal structure of Streptococcus pneumoniae pneumolysin provides key insights into early steps of pore formation.

Authors:  Sara L Lawrence; Susanne C Feil; Craig J Morton; Allison J Farrand; Terrence D Mulhern; Michael A Gorman; Kristin R Wade; Rodney K Tweten; Michael W Parker
Journal:  Sci Rep       Date:  2015-09-25       Impact factor: 4.379

5.  A new model for pore formation by cholesterol-dependent cytolysins.

Authors:  Cyril F Reboul; James C Whisstock; Michelle A Dunstone
Journal:  PLoS Comput Biol       Date:  2014-08-21       Impact factor: 4.475

6.  Preclinical evaluation of a chemically detoxified pneumolysin as pneumococcal vaccine antigen.

Authors:  Philippe Hermand; Annick Vandercammen; Emmanuel Mertens; Emmanuel Di Paolo; Vincent Verlant; Philippe Denoël; Fabrice Godfroid
Journal:  Hum Vaccin Immunother       Date:  2016-10-21       Impact factor: 3.452

7.  Otitis-Prone Children Produce Functional Antibodies to Pneumolysin and Pneumococcal Polysaccharides.

Authors:  Lea-Ann S Kirkham; Selma P Wiertsema; Karli J Corscadden; Tulia Mateus; Gemma L Mullaney; Guicheng Zhang; Peter C Richmond; Ruth B Thornton
Journal:  Clin Vaccine Immunol       Date:  2017-03-06

8.  Immunodominance in T cell responses elicited against different domains of detoxified pneumolysin PlyD1.

Authors:  Els van Westen; Martien C M Poelen; Germie P J M van den Dobbelsteen; Eliud O Oloo; Martina M Ochs; Nynke Y Rots; Cecile A C M van Els
Journal:  PLoS One       Date:  2018-03-06       Impact factor: 3.240

9.  Antibodies to PcpA and PhtD protect mice against Streptococcus pneumoniae by a macrophage- and complement-dependent mechanism.

Authors:  Lucian Visan; Nicolas Rouleau; Emilie Proust; Loïc Peyrot; Arnaud Donadieu; Martina Ochs
Journal:  Hum Vaccin Immunother       Date:  2017-12-14       Impact factor: 3.452

10.  Preclinical in vitro and in vivo profile of a highly-attenuated, broadly efficacious pneumolysin genetic toxoid.

Authors:  Ann Thanawastien; Kelsey E Joyce; Robert T Cartee; Laurel A Haines; Stephen I Pelton; Rodney K Tweten; Kevin P Killeen
Journal:  Vaccine       Date:  2020-06-10       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.